Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: GlycoNex Incorporation

Market Cap 2.85B 89.89M 78.28M 72.42M 67.84M 127M 8.48B 128M 860M 333M 4.17B 337M 330M 14.5B P/E 2024
-11.8x
P/E 2025 -11.9x
Enterprise Value 2.63B 82.95M 72.24M 66.84M 62.6M 117M 7.82B 118M 794M 307M 3.85B 311M 305M 13.38B EV / Sales 2024
154x
EV / Sales 2025 67.8x
Free-Float
80.91%
Yield 2024 *
-
Yield 2025 -
11/06 Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8 CI
14/05 GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
15/04 GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers CI
24/03 GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate CI
14/03 GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
09/12 GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program CI
25/11 Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer CI
14/11 GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
30/10/25 GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis RE
29/10/25 GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis CI
14/08/25 GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
13/06/25 GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer CI
28/05/25 GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules CI
1 day-0.39%
1 week-8.83%
Current month-0.78%
1 month-1.56%
3 months+5.86%
6 months+0.40%
Current year-1.75%
1 week 25
Extreme 25
26.5
1 month 24.65
Extreme 24.65
30
Current year 22.1
Extreme 22.1
30
1 year 20.55
Extreme 20.55
30
3 years 15.6
Extreme 15.6
33.2
5 years 15.6
Extreme 15.6
46.9
10 years 10.2
Extreme 10.2
46.9
Manager TitleAgeSince
Chief Executive Officer - 01/01/2019
Director of Finance/CFO - 01/01/2010
Investor Relations Contact - 12/11/2012
Director TitleAgeSince
Director/Board Member 64 -
Chairman - 01/02/2001
Director/Board Member - 25/05/2012
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%-8.83%-16.91%-17.72% 90.09M
+1.44%+1.36%-10.88%-12.14% 42.75B
+3.31%+9.22%+308.19%+562.02% 34.65B
+2.84%+3.80%+6.87%+34.93% 30.03B
-1.70%-7.34%+8.51%-22.34% 28B
-1.90%+2.47%+10.18%+18.13% 24.83B
-0.14%+7.06% - - 14.34B
+0.68%-3.13%+52.04%+107.47% 13.14B
-0.57%-2.83%+3.34%+1.66% 12.61B
-0.26%+0.41%+100.27%+80.69% 12.25B
Average +0.33%-0.06%+51.29%+83.63% 21.27B
Weighted average by Cap. +0.77%+0.91%+64.85%+112.17%

Financials

2024 2025
Net sales 14.7M 464K 404K 374K 350K 656K 43.78M 662K 4.44M 1.72M 21.53M 1.74M 1.7M 74.87M 37.86M 1.2M 1.04M 963K 902K 1.69M 113M 1.71M 11.44M 4.43M 55.44M 4.49M 4.39M 193M
Net income -230M -7.25M -6.32M -5.84M -5.47M -10.25M -684M -10.35M -69.43M -26.88M -336M -27.22M -26.64M -1.17B -235M -7.43M -6.47M -5.98M -5.61M -10.5M -700M -10.6M -71.1M -27.53M -344M -27.88M -27.28M -1.2B
Net Debt -442M -13.96M -12.16M -11.25M -10.54M -19.73M -1.32B -19.92M -134M -51.74M -647M -52.4M -51.27M -2.25B -220M -6.94M -6.04M -5.59M -5.24M -9.8M -654M -9.9M -66.41M -25.71M -322M -26.04M -25.48M -1.12B
Logo GlycoNex Incorporation
GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.
Employees
-
Date Price Change Volume
18/06/26 25.30 NT$ -0.39% 194,906
17/06/26 25.40 NT$ +1.20% 199,216
16/06/26 25.10 NT$ -2.33% 353,871
15/06/26 25.70 NT$ -4.10% 1,024,788
12/06/26 26.80 NT$ -3.42% 2,327,483
  1. Stock Market
  2. Stocks
  3. 4168 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!